Neurocrine Biosciences | NBIX - Sales Revenues


Neurocrine Biosciences reported $805.5M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Exelixis USD 598.66M 860K Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Halozyme Therapeutics USD 451.76M 97.76M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Prothena USD 2.42M 2M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Repligen USD 197.91M 8.91M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xoma USD 25K 5M Sep/2024